Coverage
-
September 05, 2014
A Washington, D.C., federal judge on Friday ordered the U.S. Food and Drug Administration to provide Depomed Inc. with seven years of exclusivity for its pain drug Gralise, finding the company doesn't have to prove the drug is clinically superior to a similar drug manufactured by Pfizer Inc.
2 other articles on this case.
View all »